Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) Research & Development (2023 - 2025)

Historic Research & Development for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to $9.6 million.

  • Applied Therapeutics' Research & Development fell 3525.09% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.1 million, marking a year-over-year decrease of 317.09%. This contributed to the annual value of $48.7 million for FY2024, which is 957.43% down from last year.
  • Per Applied Therapeutics' latest filing, its Research & Development stood at $9.6 million for Q3 2025, which was down 3525.09% from $9.9 million recorded in Q2 2025.
  • Applied Therapeutics' 5-year Research & Development high stood at $15.9 million for Q1 2023, and its period low was $200000.0 during Q1 2024.
  • Over the past 3 years, Applied Therapeutics' median Research & Development value was $10.8 million (recorded in 2023), while the average stood at $10.7 million.
  • Per our database at Business Quant, Applied Therapeutics' Research & Development crashed by 9874.49% in 2024 and then soared by 381850.0% in 2025.
  • Applied Therapeutics' Research & Development (Quarter) stood at $15.3 million in 2023, then fell by 23.58% to $11.7 million in 2024, then dropped by 17.91% to $9.6 million in 2025.
  • Its Research & Development stands at $9.6 million for Q3 2025, versus $9.9 million for Q2 2025 and $7.8 million for Q1 2025.